Bioventus Gains FDA Clearance for Key PNS Products

Bioventus ( (BVS) ) just unveiled an announcement.

On July 30, 2025, Bioventus Inc. announced that it received FDA 510(k) clearances for its TalisMann™ and StimTrial™ products, expanding its Peripheral Nerve Stimulation portfolio aimed at chronic pain management. This milestone presents a significant growth opportunity for Bioventus as it seeks to capitalize on the rapidly growing PNS market, which is projected to exceed $500 million by 2029. The FDA clearance allows Bioventus to offer a comprehensive PNS portfolio, enhancing its market positioning by providing non-opioid, minimally invasive therapies that address clinical needs, and facilitating broader physician adoption and payer reimbursement.

The most recent analyst rating on (BVS) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Bioventus stock, see the BVS Stock Forecast page.

Spark’s Take on BVS Stock

According to Spark, TipRanks’ AI Analyst, BVS is a Neutral.

Bioventus’s stock score is primarily impacted by its financial struggles, with ongoing profitability issues and high leverage. The technical analysis further indicates bearish sentiment. While the earnings call provided a positive outlook on strategic initiatives, the underlying financial and valuation metrics remain concerning.

To see Spark’s full report on BVS stock, click here.

More about Bioventus

Bioventus Inc. is a global leader in innovations for active healing, offering clinically proven, cost-effective products for pain treatments, surgical solutions, and restorative therapies. The company is committed to high-quality standards, evidence-based medicine, and ethical behavior, serving as a trusted partner for physicians worldwide.

Average Trading Volume: 447,304

Technical Sentiment Signal: Sell

Current Market Cap: $537.2M

Find detailed analytics on BVS stock on TipRanks’ Stock Analysis page.